In the context of BRAF/MEK inhibitors, the main cardiovascular side effects to be aware of are hypertension, pulmonary embolism, QTc prolongation, and cancer therapy–related cardiac dysfunction.4 The gene discussed is BRAF; the disease is Hypertension.